When
Eli Lilly
reports first-quarter earnings on Thursday morning, one drug will be on everyone’s minds: Mounjaro.
Excitement over the diabetes and obesity treatment has driven shares of Lilly up massively. The stock has soared 32% over the past 12 months, and is up about 3% so far this year. It trades at 41 times earnings expected over the next 12 months, according to FactSet.
